result investor day wing
reiter buy rate increas price target
upgrad stock back august
thought could upsid near term estim second
consecut larg beat demonstr oper leverag
think compani may turn corner toward sustain profit
would surpris manag provid greater clariti around
longer term margin target well commerci initi
decemb investor day back print view qualiti beat
believ impli outlook leav addit room upsid
broad out-performance across revenu beat us/consensu
product segment outperform model
touch light vs street compani still deliv oper
margin beat due better sg think shift pharmaci
channel could result signific sourc leverag line item
time ep beat street ep loss pleas see
exhibit inform
guidanc rais consensu impli revenu
higher consensu think push toward pharmaci
access on-going roll-out medicar patient well
roll-out season strength could drive upsid beyond
manag opex guidanc year impli mid-single-digit
oper margin think compani abl deliv
price target account higher estim increas sale
forecast slightli guidanc blue sky scenario
could see upsid beyond bake greater type
adopt verili type insulin initi well signific turn
toward sustain margin expans new rev/ep
compar previou pleas see exhibit
detail estim chang
chang made note
buy chang
page analyst certif
perform rel
inc design commerci
platform use peopl
profit loss summari
growth margin
non-intens
cgm devic use diabet patient monitor
glycem level view compani technolog best-
in-class type platform vs competit offer
new platform roll-out could lead sustain revenu
upsid given under-penetrated natur cgm de-risk
guidanc set stage long-term innov verili
market expans
popul manag work secur greater patient
access pharmaci channel believ price
differenti cgm self-monitor blood glucos test
smbg use finger stick draw blood test blood sugar
set narrow potenti drive greater adopt well
think oper leverag may come faster
previous contempl could driven entri new
channel mix shift pharmaci dme pressur
off-set reduct initi
lower cost transmitt on-going scale driven
higher volum increas product facil
price target base ev/revenu
billion sale growth toward high end med-tech
believ deserv premium multipl vs peer note
sale estim includ contribut pipelin
verili addit end market japan
chang net debt
average cost debt
risk invest thesi
thesi price target could risk compani unabl
drive adopt cgm technolog level
could occur diabet patient clinician believ
technolog better easier use compani unabl
drive sensor price level make afford
well manag unabl drive leverag profit
forecast could risk
exhibit varianc estim
varianc estim
varianc estim
varianc estim
varianc estim
estimate
estimate
estimate
estimate
inc revenue servic freight accessori etc
sale
sale
sale growth rate north expect could
sustain growth clip next year believ stock deserv
valu ev/sal multipl premium vs peer price target assum multipl
sale compar peer comp set growth rate
could upsid number compani begin commerci
verili type insulin initi current factor revenu
program model
thesi price target could risk compani unabl drive adopt
cgm technolog level model could occur diabet patient
clinician believ technolog better easier use compani
unabl drive sensor price level make afford widespread
adopt well manag unabl drive leverag profit forecast
could risk
profit loss account
sale
incom oper
incom oper
incom oper
incom oper
incom equiti invest
net incom provis incom tax
provis incom tax
incom oper
incom oper
incom oper
incom oper
sharecount dilut q/q quarter y/i annual
cash equival
short-term market securit avail sale
prepaid current asset
properti plant equip net
current portion long-term debt
account payabl accru liabil
accru payrol relat expens
current portion defer revenu
prefer stock par share author none issu outstand
total liabil stockhold equiti
total liabil stockhold equiti
total liabil stockhold equiti
total liabil stockhold equiti
oper
oper
oper
oper
depreci amort
non-cash issuanc common stock
impair intang asset
chang asset liabil net effect acquisit
prepaid expens asset
account payabl accru liabil
accru payrol relat expens
defer rent liabil
total chang work capit
net cash oper
net cash oper
net cash oper
net cash oper
invest
invest
invest
invest
purchas market secur
proce matur market secur
purchas pp
acquisit net cash acquir
net cash invest
net cash invest
net cash invest
net cash invest
financ
financ
financ
financ
net proce issuanc common stock
payment acquisit relat conting consider liabil
proce issuanc convert debt net issuanc cost
proce short-term borrow
repay short-term borrow
repay long-term debt
net cash financ
net cash financ
net cash financ
net cash financ
net chang cash equival
net chang cash equival
net chang cash equival
net chang cash equival
 begin period
 end period
